![]() |
|
|
Vol. 30, Issue 6, 734-738, June 2002
Department of Molecular and Cellular Pathology, Ninewells Hospital
and Medical School, Dundee, United Kingdom (B.T.E., B.B.); and Lilly
Research Laboratories, Eli Lilly and Company, Lilly Corporate Center,
Indianapolis, Indiana (S.E., J.W.)
UGT1A6 and UGT1A9 have both been demonstrated to rapidly
glucuronidate simple phenolic compounds. A series of simple phenols were selected and screened with both isoforms and then used as model
substrates for the generation of Vmax and
Km values. UGT1A6 showed a more restricted
acceptance of phenolic substrates compared with UGT1A9. However, the
affinity of UGT1A6 for these compounds exhibited higher
Km values than UGT1A9, although rates of
turnover were similar. Molecular surface-weighted holistic invariant
molecular descriptors were generated for each substrate and used to
produce the first quantitative structure activity relationship models generated for expressed human UGTs. Models relating log of the Km value to the generated descriptors
correlated well with the experimental data
r2 value of 0.996 for UGT1A6 and
r2 value of 0.83 for UGT1A9. Cross
validation by a leave-one-out method also showed good predictive
capability within the subset with a q2 value
of 0.98 for UGT1A6 and q2 value of 0.73 for
UGT1A9. Empirically, UGT1A6 Vmax decreased as the 4-substituent increased in size, and a trend was observed when
UGT1A6 Vmax was plotted against molecular
volume. The larger UGT1A6 substrates were typified by low activity and
lower Km values than their smaller
counterparts. Extrapolating from this, it was demonstrated that phenols
with large 4-substituents, which were not UGT1A6 substrates, could
inhibit 4-ethylphenol glucuronidation. The
Km values for UGT1A9 showed a similar
relationship to UGT1A6 but with much lower
Km values and greater variability in range of this value.
This article has been cited by other articles:
![]() |
Y. Zhen, K. W. Krausz, C. Chen, J. R. Idle, and F. J. Gonzalez Metabolomic and Genetic Analysis of Biomarkers for Peroxisome Proliferator-Activated Receptor {alpha} Expression and Activation Mol. Endocrinol., September 1, 2007; 21(9): 2136 - 2151. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Kuehl, J. W. Lampe, J. D. Potter, and J. Bigler GLUCURONIDATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS: IDENTIFYING THE ENZYMES RESPONSIBLE IN HUMAN LIVER MICROSOMES Drug Metab. Dispos., July 1, 2005; 33(7): 1027 - 1035. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Krishnaswamy, Q. Hao, L. L. von Moltke, D. J. Greenblatt, and M. H. Court EVALUATION OF 5-HYDROXYTRYPTOPHOL AND OTHER ENDOGENOUS SEROTONIN (5-HYDROXYTRYPTAMINE) ANALOGS AS SUBSTRATES FOR UDP-GLUCURONOSYLTRANSFERASE 1A6 Drug Metab. Dispos., August 1, 2004; 32(8): 862 - 869. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Kuehl and S. E. Murphy N-GLUCURONIDATION OF NICOTINE AND COTININE BY HUMAN LIVER MICROSOMES AND HETEROLOGOUSLY EXPRESSED UDP-GLUCURONOSYLTRANSFERASES Drug Metab. Dispos., November 1, 2003; 31(11): 1361 - 1368. [Abstract] [Full Text] [PDF] |
||||